Celerity Biosciences Revenue and Competitors

Superior, CO

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Celerity Biosciences's estimated annual revenue is currently $775k per year.(i)
  • Celerity Biosciences's estimated revenue per employee is $155,000

Employee Data

  • Celerity Biosciences has 5 Employees.(i)
  • Celerity Biosciences grew their employee count by -29% last year.

Celerity Biosciences's People

NameTitleEmail/Phone
1
Director Marketing Operations & Product StrategyReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.7M110%N/AN/A
#2
$2.8M1813%N/AN/A
#3
$70.2M453-1%N/AN/A
#4
$1.6M10-66%N/AN/A
#5
$3.7M24-8%N/AN/A
#6
$2.9M3728%N/AN/A
#7
$3.1M2025%N/AN/A
#8
$2.5M16-20%N/AN/A
#9
$9.1M590%N/AN/A
#10
$4.2M27-7%N/AN/A
Add Company

What Is Celerity Biosciences?

Celerity Biosciences integrates rare tissue procurement with anatomic and molecular pathology laboratory services. We are committed to empowering scientists by swiftly delivering quality services. Our laboratory services include immunohistochemistry, molecular pathology, conventional pathology and digital image analysis, all performed in our ISO 15189 accredited facilities. We operate several Illumina® sequencers and the Ion Torrent from Thermo Fisher as well as a full menu of Archer® and Illumina® panels. We offer more than 400 IHC antibodies run on VENTANA automated platforms. Our bio specimen services enable access to an extensive bank of retrospective samples and prospective sample procurement programs which may be integrated into lab services or as a stand alone service. Our commercial laboratory practices and regional and global provider networks are a key component of Celerity’s bio specimen services.

keywords:N/A

N/A

Total Funding

5

Number of Employees

$775k

Revenue (est)

-29%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.4M50%N/A
#2
$0.4M60%N/A
#3
$0.4M60%N/A
#4
$0.4M60%N/A
#5
$0.5M7-63%N/A